{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:52:05Z","timestamp":1784735525115,"version":"3.55.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.10.009","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:41:54Z","timestamp":1760546514000},"page":"e270-e282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Breast Cancer Risk After Chest Radiotherapy in Hodgkin Lymphoma Survivors: A Comprehensive Overview"],"prefix":"10.1016","volume":"26","author":[{"given":"Amanda","family":"Caruso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena Emanuela","family":"Laddaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Maria","family":"Moramarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clorinda Maria Luisa","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-1665","authenticated-orcid":false,"given":"Francesco","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.10.009_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/707542","article-title":"Outcome of very late relapse in patients with Hodgkin\u2019s Lymphomas","volume":"2011","author":"Gaudio","year":"2011","journal-title":"Adv Hematol"},{"issue":"8","key":"10.1016\/j.clml.2025.10.009_bib0002","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/j.clml.2020.03.006","article-title":"Long-term Hodgkin Lymphoma survivors: A glimpse of what happens 10 years after treatment","volume":"20","author":"Laddaga","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk. agosto"},{"issue":"7","key":"10.1016\/j.clml.2025.10.009_bib0003","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1016\/j.clml.2025.10.009_bib0004","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin\u2019s lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2025.10.009_bib0005","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1200\/JCO.2008.20.7738","article-title":"Radiation dose and breast cancer risk in the childhood cancer survivor study","volume":"27","author":"Inskip","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"10.1016\/j.clml.2025.10.009_bib0006","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1471-2407-12-197","article-title":"Risk of second breast cancer in female Hodgkin\u2019s lymphoma survivors: a meta-analysis","volume":"12","author":"Ibrahim","year":"2012","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clml.2025.10.009_bib0007","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA."},{"issue":"22","key":"10.1016\/j.clml.2025.10.009_bib0008","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a National Cohort Study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"21","key":"10.1016\/j.clml.2025.10.009_bib0009","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1200\/JCO.2013.54.4601","article-title":"Breast cancer after chest radiation therapy for childhood cancer","volume":"32","author":"Moskowitz","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0010","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/jamaoncol.2017.4887","article-title":"Association of treatment for Hodgkin lymphoma with estrogen receptor status of subsequent breast cancers","volume":"4","author":"Withrow","year":"2018","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.clml.2025.10.009_bib0011","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ejca.2010.02.015","article-title":"Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group","volume":"46","author":"Sardanelli","year":"2010","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"2","key":"10.1016\/j.clml.2025.10.009_bib0012","first-page":"75","article-title":"American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0013","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1148\/radiol.2363040811","article-title":"Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution","volume":"236","author":"Kuhl","year":"2005","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.clml.2025.10.009_bib0014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.mri.2015.10.014","article-title":"Breast MRI background parenchymal enhancement (BPE) correlates with the risk of breast cancer","volume":"34","author":"Telegrafo","year":"2016","journal-title":"Magn Reson Imaging"},{"issue":"5","key":"10.1016\/j.clml.2025.10.009_bib0015","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00330-001-1213-1","article-title":"Classification of hypervascularized lesions in CE MR imaging of the breast","volume":"12","author":"Baum","year":"2002","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0016","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13014-019-1360-7","article-title":"Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin\u2019s disease","volume":"14","author":"Lautenschlaeger","year":"2019","journal-title":"Radiat Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.10.009_bib0017","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.2023020940","article-title":"Risk of male breast cancer after Hodgkin lymphoma","volume":"142","author":"de Vries","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2025.10.009_bib0018","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.3390\/cancers16234091","article-title":"Long-term breast cancer risk in Hodgkin lymphoma survivors: evaluating background parenchymal enhancement and radiotherapy-induced toxicity","volume":"16","author":"Laddaga","year":"2024","journal-title":"Cancers"},{"issue":"26","key":"10.1016\/j.clml.2025.10.009_bib0019","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.clml.2025.10.009_bib0020","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1634\/theoncologist.2011-0451","article-title":"Risk, characteristics, and prognosis of breast cancer after Hodgkin\u2019s lymphoma","volume":"17","author":"Veit-Rubin","year":"2012","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.clml.2025.10.009_bib0021","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/bjc.2013.219","article-title":"Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors","volume":"108","author":"Cooke","year":"2013","journal-title":"Br J Cancer."},{"issue":"13","key":"10.1016\/j.clml.2025.10.009_bib0022","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin\u2019s disease","volume":"95","author":"Van Leeuwen","year":"2003","journal-title":"JNCI J Natl Cancer Inst."},{"issue":"4","key":"10.1016\/j.clml.2025.10.009_bib0023","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ijrobp.2017.07.016","article-title":"Breast cancer risk after radiation therapy for Hodgkin lymphoma: influence of gonadal hormone exposure","volume":"99","author":"Krul","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0024","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2009.01.040","article-title":"Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer","volume":"74","author":"Diallo","year":"2009","journal-title":"Int J Radiat Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.10.009_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/mp.12462","article-title":"AAPM TG 158: measurement and calculation of doses outside the treated volume from external-beam radiation therapy","volume":"44","author":"Kry","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.clml.2025.10.009_bib0026","first-page":"20","article-title":"Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy","volume":"7","author":"Russell","year":"2017","journal-title":"Clin Transl Radiat Oncol."},{"issue":"2","key":"10.1016\/j.clml.2025.10.009_bib0027","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.1985.3.2.207","article-title":"Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin\u2019s disease","volume":"3","author":"Zittoun","year":"1985","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"19","key":"10.1016\/j.clml.2025.10.009_bib0028","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"14","key":"10.1016\/j.clml.2025.10.009_bib0029","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"19","key":"10.1016\/j.clml.2025.10.009_bib0030","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.clml.2025.10.009_bib0031","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ijrobp.2024.04.015","volume":"120","author":"Rosenbrock","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clml.2025.10.009_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103326","article-title":"The impact of modern radiotherapy on radiation-induced late sequelae: focus on early-stage mediastinal classical Hodgkin Lymphoma. A critical review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)","volume":"161","author":"Iorio","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0033","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2016.10.004","article-title":"Secondary breast cancer risk by radiation volume in women with Hodgkin Lymphoma","volume":"97","author":"Conway","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clml.2025.10.009_bib0034","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1748-717X-2-13","article-title":"A comparison of mantle versus involved-field radiotherapy for Hodgkin\u2019s lymphoma: reduction in normal tissue dose and second cancer risk","volume":"2","author":"Koh","year":"2007","journal-title":"Radiat Oncol Lond Engl."},{"issue":"10","key":"10.1016\/j.clml.2025.10.009_bib0035","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41568-020-0275-9","article-title":"In vivo functional screening for systems-level integrative cancer genomics","volume":"20","author":"Weber","year":"2020","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"10.1016\/j.clml.2025.10.009_bib0036","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/pbc.24861","article-title":"The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma","volume":"61","author":"Maraldo","year":"2014","journal-title":"Pediatr Blood Cancer."},{"issue":"12","key":"10.1016\/j.clml.2025.10.009_bib0037","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","article-title":"Second malignancy risk associated with treatment of Hodgkin\u2019s lymphoma: meta-analysis of the randomised trials","volume":"17","author":"Franklin","year":"2006","journal-title":"Ann Oncol."},{"issue":"4","key":"10.1016\/j.clml.2025.10.009_bib0038","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2015.11.046","article-title":"Radiation-related new primary solid cancers in the childhood cancer survivor study: comparative Radiation dose response and modification of treatment effects","volume":"94","author":"Inskip","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0039","first-page":"6","article-title":"Radiotherapy in early stage classical Hodgkin lymphoma: past, present and future","volume":"4","author":"Zhang","year":"2015","journal-title":"Chin Clin Oncol."},{"issue":"5","key":"10.1016\/j.clml.2025.10.009_bib0040","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"16","key":"10.1016\/j.clml.2025.10.009_bib0041","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years","volume":"20","author":"Dores","year":"2002","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1016\/j.clml.2025.10.009_bib0042","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-141-8-200410190-00006","article-title":"Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"141","author":"Kenney","year":"2004","journal-title":"Ann Intern Med."},{"issue":"16","key":"10.1016\/j.clml.2025.10.009_bib0043","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.10.009_bib0044","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology State-of-the-art review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncology."},{"issue":"5","key":"10.1016\/j.clml.2025.10.009_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70134","article-title":"Late cardiac toxicity after anthracyclines and radiotherapy for lymphoma: a regression analysis of dose-response","volume":"43","author":"Nyg\u00e5rd","year":"2025","journal-title":"Hematol Oncol."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0046","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12885-024-13305-3","article-title":"A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients","volume":"25","author":"Dai","year":"2025","journal-title":"BMC Cancer."},{"issue":"17","key":"10.1016\/j.clml.2025.10.009_bib0047","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.3390\/ijms26178662","article-title":"Sequencing anti-CD19 therapies in diffuse large B-cell lymphoma: from mechanistic insights to clinical strategies","volume":"26","author":"Laddaga","year":"2025","journal-title":"Int J Mol Sci."},{"issue":"14","key":"10.1016\/j.clml.2025.10.009_bib0048","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2016.70.9709","article-title":"Risk of second cancer in hodgkin lymphoma survivors and influence of Family history","volume":"35","author":"Sud","year":"2017","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1016\/j.clml.2025.10.009_bib0049","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/annonc\/mdu017","article-title":"Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma","volume":"25","author":"Horst","year":"2014","journal-title":"Ann Oncol."},{"issue":"24","key":"10.1016\/j.clml.2025.10.009_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415530","article-title":"Obesity and risk for lymphoma: possible role of leptin","volume":"23","author":"Jim\u00e9nez-Cortegana","year":"2022","journal-title":"Int J Mol Sci."},{"issue":"10","key":"10.1016\/j.clml.2025.10.009_bib0051","first-page":"1027","article-title":"Molecular changes in second primary lung and breast cancers after therapy for Hodgkin\u2019s disease","volume":"9","author":"Behrens","year":"2000","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol."},{"issue":"12","key":"10.1016\/j.clml.2025.10.009_bib0052","first-page":"3813","article-title":"Rare variants of ATM and risk for Hodgkin\u2019s disease and radiation-associated breast cancers","volume":"8","author":"Offit","year":"2002","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"24","key":"10.1016\/j.clml.2025.10.009_bib0053","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2003.12.042","article-title":"TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin\u2019s disease with second primary neoplasms","volume":"21","author":"Nichols","year":"2003","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1016\/j.clml.2025.10.009_bib0054","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nm.2407","article-title":"Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin\u2019s lymphoma","volume":"17","author":"Best","year":"2011","journal-title":"Nat Med."},{"issue":"11","key":"10.1016\/j.clml.2025.10.009_bib0055","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/bjc.2013.219","article-title":"Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors","volume":"108","author":"Cooke","year":"2013","journal-title":"Br J Cancer."},{"issue":"11","key":"10.1016\/j.clml.2025.10.009_bib0056","article-title":"Genome-wide association study to identify susceptibility loci that modify radiation-related risk for breast cancer after childhood cancer","volume":"109","author":"Morton","year":"2017","journal-title":"JNCI J Natl Cancer Inst [Internet]"},{"issue":"10","key":"10.1016\/j.clml.2025.10.009_bib0057","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1182\/blood-2005-04-1535","article-title":"Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors","volume":"106","author":"Hill","year":"2005","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.clml.2025.10.009_bib0058","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bjc.6604244","article-title":"Family history of cancer as a risk factor for second malignancies after Hodgkin\u2019s lymphoma","volume":"98","author":"Andersson","year":"2008","journal-title":"Br J Cancer."},{"issue":"5","key":"10.1016\/j.clml.2025.10.009_bib0059","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ijc.22414","article-title":"Risk of second malignant neoplasms among lymphoma patients with a family history of cancer","volume":"120","author":"Landgren","year":"2007","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.clml.2025.10.009_bib0060","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2016.70.9709","article-title":"Risk of second cancer in hodgkin lymphoma survivors and influence of Family history","volume":"35","author":"Sud","year":"2017","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.clml.2025.10.009_bib0061","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028559","article-title":"Radiation-induced carcinogenesis: mechanistically based differences between gamma-rays and neutrons, and interactions with DMBA","volume":"6","author":"Shuryak","year":"2011","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0062","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/2000-1967-084","article-title":"Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis","volume":"109","author":"Molin","year":"2004","journal-title":"Ups J Med Sci"},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0063","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41416-020-0942-3","article-title":"Radiation-induced bystander and abscopal effects: important lessons from preclinical models","volume":"123","author":"Daguenet","year":"2020","journal-title":"Br J Cancer."},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.009_bib0064","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1182\/blood-2024-202113","article-title":"Abscopal effect of radiotherapy and Nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma: results of the International GHSG Phase II Aern trial","volume":"144","author":"Br\u00f6ckelmann","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0065","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1667\/RR15048.1","article-title":"Complete local and abscopal responses from a combination of radiation and Nivolumab in refractory Hodgkin\u2019s lymphoma","volume":"190","author":"Qin","year":"2018","journal-title":"Radiat Res."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0066","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijrobp.2020.02.636","article-title":"Abscopal regressions of lymphoma after involved-site radiation therapy confirmed by positron emission tomography","volume":"108","author":"MacManus","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clml.2025.10.009_bib0067","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.017","article-title":"Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody","volume":"66","author":"Michot","year":"2016","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"11","key":"10.1016\/j.clml.2025.10.009_bib0068","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/cancers9110147","article-title":"Clinical and functional assays of radiosensitivity and radiation-induced second cancer","volume":"9","author":"Habash","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2025.10.009_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1470431","article-title":"Detection of radiosensitive subpopulations ex-vivo with Raman microspectroscopy","volume":"15","author":"Meade","year":"2025","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0070","doi-asserted-by":"crossref","first-page":"e3269","DOI":"10.1002\/hon.3269","article-title":"Future perspectives of radiation therapy for Hodgkin Lymphoma: risk-adapted, response-adapted, and safer than before","volume":"42","author":"Saddi","year":"2024","journal-title":"Hematol Oncol."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0071","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/asheducation-2016.1.316","article-title":"Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?","volume":"2016","author":"Johnson","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0072","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1470-2045(23)00019-0","article-title":"Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study","volume":"24","author":"Mauz-K\u00f6rholz","year":"2023","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0073","first-page":"13","article-title":"Risk- and response-adapted strategies for the management of Hodgkin lymphoma","volume":"4","author":"Remer","year":"2015","journal-title":"Chin Clin Oncol."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0074","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/asheducation-2016.1.316","article-title":"Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?","volume":"2016","author":"Johnson","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"12","key":"10.1016\/j.clml.2025.10.009_bib0075","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1200\/JCO.18.00378","article-title":"Population-based assessment of the Association between Magnetic Resonance Imaging Background parenchymal Enhancement and future primary breast cancer risk","volume":"37","author":"Arasu","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"4","key":"10.1016\/j.clml.2025.10.009_bib0076","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ijc.31370","article-title":"MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women","volume":"143","author":"Brooks","year":"2018","journal-title":"Int J Cancer."},{"issue":"1103","key":"10.1016\/j.clml.2025.10.009_bib0077","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190417","article-title":"Association between MRI background parenchymal enhancement and lymphovascular invasion and estrogen receptor status in invasive breast cancer","volume":"92","author":"Li","year":"2019","journal-title":"Br J Radiol."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0078","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1148\/radiol.11102156","article-title":"Background parenchymal enhancement at breast MR imaging and breast cancer risk","volume":"260","author":"King","year":"2011","journal-title":"Radiology."},{"issue":"12","key":"10.1016\/j.clml.2025.10.009_bib0079","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s00330-012-2553-8","article-title":"Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI","volume":"22","author":"King","year":"2012","journal-title":"Eur Radiol."},{"issue":"6","key":"10.1016\/j.clml.2025.10.009_bib0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/tbj.12002","article-title":"Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging","volume":"18","author":"King","year":"2012","journal-title":"Breast J"},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0081","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1148\/radiol.2016160284","article-title":"Comparison of background parenchymal enhancement at contrast-enhanced spectral mammography and breast MR imaging","volume":"282","author":"Sogani","year":"2017","journal-title":"Radiology."},{"issue":"2","key":"10.1016\/j.clml.2025.10.009_bib0082","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.acra.2015.09.010","article-title":"Breast background parenchymal enhancement on screening magnetic resonance imaging in women who received chest radiotherapy for childhood Hodgkin\u2019s lymphoma","volume":"23","author":"Zeng","year":"2016","journal-title":"Acad Radiol."},{"key":"10.1016\/j.clml.2025.10.009_bib0083","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13058-015-0577-0","article-title":"Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1\/2 mutation carriers","volume":"17","author":"Wu","year":"2015","journal-title":"Breast Cancer Res BCR."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0084","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.acra.2018.03.013","article-title":"Relationship between background parenchymal enhancement on high-risk screening MRI and future breast cancer risk","volume":"26","author":"Grimm","year":"2019","journal-title":"Acad Radiol."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.acra.2018.03.013","article-title":"Relationship between background parenchymal enhancement on high-risk screening MRI and future breast cancer risk","volume":"26","author":"Grimm","year":"2019","journal-title":"Acad Radiol."},{"issue":"9","key":"10.1016\/j.clml.2025.10.009_bib0086","doi-asserted-by":"crossref","first-page":"dju207","DOI":"10.1093\/jnci\/dju207","article-title":"Risk of premature menopause after treatment for Hodgkin\u2019s lymphoma","volume":"106","author":"Swerdlow","year":"2014","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"10.1016\/j.clml.2025.10.009_bib0087","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dmz027","article-title":"Ovarian damage from chemotherapy and current approaches to its protection","volume":"25","author":"Spears","year":"2019","journal-title":"Hum Reprod Update"},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0088","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1631\/jzus.B2000344","article-title":"DNA alkylation lesion repair: outcomes and implications in cancer chemotherapy","volume":"22","author":"Peng","year":"2021","journal-title":"J Zhejiang Univ Sci B"},{"issue":"2","key":"10.1016\/j.clml.2025.10.009_bib0089","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijrobp.2009.09.004","article-title":"Radiation-associated breast tumors display a distinct gene expression profile","volume":"76","author":"Broeks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.clml.2025.10.009_bib0090","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12605","article-title":"Mutational signatures of ionizing radiation in second malignancies","volume":"7","author":"Behjati","year":"2016","journal-title":"Nat Commun."},{"issue":"10","key":"10.1016\/j.clml.2025.10.009_bib0091","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood-2018-07-862607","article-title":"Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma","volume":"133","author":"Opstal-van Winden","year":"2019","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.clml.2025.10.009_bib0092","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.34065","article-title":"Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: results from a population-based cohort","volume":"128","author":"Wong","year":"2022","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0093","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1748-717X-4-19","article-title":"Clinical outcome of breast cancer occurring after treatment for Hodgkin\u2019s lymphoma: case-control analysis","volume":"4","author":"El-Din","year":"2009","journal-title":"Radiat Oncol."},{"issue":"18","key":"10.1016\/j.clml.2025.10.009_bib0094","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1200\/JCO.2010.32.4079","article-title":"Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin\u2019s lymphoma: a multi-institutional, matched cohort study","volume":"29","author":"Elkin","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0095","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/cdev.12013","article-title":"Academic achievement trajectories of homeless and highly mobile students: resilience in the context of chronic and acute risk","volume":"84","author":"Cutuli","year":"2013","journal-title":"Child Dev."},{"issue":"13","key":"10.1016\/j.clml.2025.10.009_bib0096","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.ejca.2015.05.024","article-title":"Management of breast cancer after Hodgkin\u2019s lymphoma and paediatric cancer","volume":"51","author":"Terenziani","year":"2015","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clml.2025.10.009_bib0097","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1245\/s10434-022-11947-w","article-title":"Surgical management and contralateral breast cancer risk in women with history of radiation therapy for Hodgkin lymphoma: results from a population-based cohort","volume":"29","author":"Eisenberg","year":"2022","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"10.1016\/j.clml.2025.10.009_bib0098","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.2000.18.4.765","article-title":"Management of breast cancer after Hodgkin\u2019s disease","volume":"18","author":"Wolden","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0099","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1524-4741.2001.007001046.x","article-title":"Clinical and pathologic features of breast cancers in women treated for Hodgkin\u2019s disease: a case-control study","volume":"7","author":"Janov","year":"2001","journal-title":"Breast J"},{"issue":"2","key":"10.1016\/j.clml.2025.10.009_bib0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0360-3016(00)01481-4","article-title":"Breast cancer after mantle irradiation for Hodgkin\u2019s disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2","volume":"49","author":"Gaffney","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"10.1016\/j.clml.2025.10.009_bib0101","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdl399","article-title":"Breast cancer in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma survivors","volume":"18","author":"Sanna","year":"2007","journal-title":"Ann Oncol."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0102","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/1078-0432.CCR-06-1490","article-title":"Radiation effects on development of HER2-positive breast carcinomas","volume":"13","author":"Castiglioni","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0103","article-title":"Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays. Guan XY, curatore","volume":"10","author":"Yang","year":"2015","journal-title":"PLOS ONE."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.critrevonc.2011.01.005","article-title":"Breast cancer occurred after Hodgkin\u2019s disease: clinico-pathological features, treatments and outcome: analysis of 214 cases","volume":"81","author":"Cutuli","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.10.009_bib0105","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.bjc.6605215","article-title":"The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage","volume":"101","author":"Howell","year":"2009","journal-title":"Br J Cancer."},{"issue":"34","key":"10.1016\/j.clml.2025.10.009_bib0106","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1200\/JCO.2010.29.5683","article-title":"Long-term survival among patients with Hodgkin\u2019s lymphoma who developed breast cancer: a population-based study","volume":"28","author":"Milano","year":"2010","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.clml.2025.10.009_bib0107","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4065\/78.6.708","article-title":"Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience","volume":"78","author":"Wahner-Roedler","year":"2003","journal-title":"Mayo Clin Proc."},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0108","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1524-4741.2010.00904.x","article-title":"Breast cancer following Hodgkin\u2019s disease: the experience of the University of Florence: Breast cancer following Hodgkin\u2019s disease","volume":"16","author":"Meattini","year":"2010","journal-title":"Breast J."},{"issue":"2","key":"10.1016\/j.clml.2025.10.009_bib0109","first-page":"128","article-title":"Breast conserving surgery in locoregional treatment of breast carcinoma after Hodgkin lymphoma]","volume":"16","author":"Haberer","year":"2012","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol."},{"key":"10.1016\/j.clml.2025.10.009_bib0110","series-title":"curatori. Breast Cancer: Innovations in Research and Management","first-page":"1","author":"Veronesi","year":"2017"},{"issue":"35","key":"10.1016\/j.clml.2025.10.009_bib0111","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.20.00562","article-title":"Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer from the International Guideline Harmonization Group","volume":"38","author":"Mulder","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2025.10.009_bib0112","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2012.46.5732","article-title":"Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma","volume":"31","author":"Ng","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"4","key":"10.1016\/j.clml.2025.10.009_bib0113","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6602974","article-title":"High incidence of late effects found in Hodgkin\u2019s lymphoma survivors, following recall for breast cancer screening","volume":"94","author":"Greenfield","year":"2006","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0114","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1524-4741.2007.00524.x","article-title":"Mammographic screening in women at increased risk of breast cancer after treatment of Hodgkin\u2019s disease","volume":"14","author":"Kwong","year":"2008","journal-title":"Breast J"},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/annonc\/mdm440","article-title":"Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin\u2019s lymphoma","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"7","key":"10.1016\/j.clml.2025.10.009_bib0116","doi-asserted-by":"crossref","first-page":"djw010","DOI":"10.1093\/jnci\/djw010","article-title":"Impact of early breast cancer screening on mortality among young survivors of childhood Hodgkin\u2019s lymphoma","volume":"108","author":"Hodgson","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.clml.2025.10.009_bib0117","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2012.46.5732","article-title":"Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma","volume":"31","author":"Ng","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"8","key":"10.1016\/j.clml.2025.10.009_bib0118","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2017.0693","article-title":"Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer","volume":"317","author":"Turcotte","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clml.2025.10.009_bib0119","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/bjc.2017.476","article-title":"High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors","volume":"118","author":"De Vries","year":"2018","journal-title":"Br J Cancer."},{"issue":"12","key":"10.1016\/j.clml.2025.10.009_bib0120","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/annonc\/mdr013","article-title":"Reduced incidence of second solid tumors in survivors of childhood Hodgkin\u2019s lymphoma treated without radiation therapy","volume":"22","author":"Barbaro","year":"2011","journal-title":"Ann Oncol."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0121","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1038\/s41467-023-39996-z","article-title":"Obesity-associated changes in molecular biology of primary breast cancer","volume":"14","author":"Nguyen","year":"2023","journal-title":"Nat Commun."},{"issue":"13","key":"10.1016\/j.clml.2025.10.009_bib0122","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3390\/nu15132839","article-title":"CEBP-\u03b2 and PLK1 as potential mediators of the breast cancer\/obesity crosstalk: In Vitro and In Silico analyses","volume":"15","author":"Accattatis","year":"2023","journal-title":"Nutrients."},{"issue":"2","key":"10.1016\/j.clml.2025.10.009_bib0123","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13358","article-title":"Obesity and endocrine therapy resistance in breast cancer: mechanistic insights and perspectives","volume":"23","author":"Barone","year":"2022","journal-title":"Obes Rev Off J Int Assoc Study Obes."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0124","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12964-025-02262-4","article-title":"Adipocyte\/tumor cell crosstalk via IGF-1\/TXNIP axis promotes malignancy and endocrine resistance in breast cancer","volume":"23","author":"Caruso","year":"2025","journal-title":"Cell Commun Signal CCS."},{"issue":"21","key":"10.1016\/j.clml.2025.10.009_bib0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112941","article-title":"Proteomic profiling of extracellular vesicles released by leptin-treated breast cancer cells: a potential role in cancer metabolism","volume":"23","author":"Gelsomino","year":"2022","journal-title":"Int J Mol Sci."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0126","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/cancers15010324","article-title":"Physical exercise and the hallmarks of breast cancer: a narrative review","volume":"15","author":"Garc\u00eda-Chico","year":"2023","journal-title":"Cancers."},{"issue":"5","key":"10.1016\/j.clml.2025.10.009_bib0127","first-page":"823","article-title":"Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence among women at high risk of breast cancer in the NSABP P-1 trial","volume":"23","author":"Land","year":"2014","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol."},{"key":"10.1016\/j.clml.2025.10.009_bib0128","series-title":"Clinicaltrials.Gov. Identifier: NCT01196936","article-title":"Low-dose tamoxifen citrate in reducing breast cancer risk in radiation-induced cancer survivors (LDTam)","year":"2020"},{"issue":"5","key":"10.1016\/j.clml.2025.10.009_bib0129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clbc.2013.06.001","article-title":"Prophylactic mastectomy: a treatment alternative for Hodgkin survivors?","volume":"13","author":"Boucher","year":"2013","journal-title":"Clin Breast Cancer."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00000421-200102000-00005","article-title":"Lumpectomy and breast irradiation for breast cancer arising after previous radiotherapy for Hodgkin\u2019s disease or lymphoma","volume":"24","author":"Deutsch","year":"2001","journal-title":"Am J Clin Oncol."},{"issue":"3","key":"10.1016\/j.clml.2025.10.009_bib0131","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0167-8140(01)00337-1","article-title":"Breast cancer occurred after treatment for Hodgkin\u2019s disease: analysis of 133 cases","volume":"59","author":"Cutuli","year":"2001","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol."},{"issue":"5","key":"10.1016\/j.clml.2025.10.009_bib0132","doi-asserted-by":"crossref","first-page":"R828","DOI":"10.1186\/bcr1310","article-title":"A new option for early breast cancer patients previously irradiated for Hodgkin\u2019s disease: intraoperative radiotherapy with electrons (ELIOT)","volume":"7","author":"Intra","year":"2005","journal-title":"Breast Cancer Res BCR"},{"issue":"2","key":"10.1016\/j.clml.2025.10.009_bib0133","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/COC.0b013e318180c880","article-title":"Partial breast brachytherapy as the primary treatment for breast cancer diagnosed after mantle radiation therapy for Hodgkin\u2019s disease","volume":"32","author":"Chadha","year":"2009","journal-title":"Am J Clin Oncol."},{"issue":"Suppl 3","key":"10.1016\/j.clml.2025.10.009_bib0134","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0960-9776(11)70304-6","article-title":"Local therapy for breast cancer in malignant lymphoma survivors","volume":"20","author":"Intra","year":"2011","journal-title":"Breast Edinb Scotl."},{"issue":"1","key":"10.1016\/j.clml.2025.10.009_bib0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s13566-016-0262-7","article-title":"Comparison of treatment modalities for breast cancer arising in Hodgkin\u2019s lymphoma survivors","volume":"6","author":"Burt","year":"2017","journal-title":"J Radiat Oncol."},{"key":"10.1016\/j.clml.2025.10.009_bib0136","series-title":"curatori. Breast Cancer [Internet]","first-page":"399","article-title":"Breast cancer in lymphoma survivors","author":"Intra","year":"2017"},{"key":"10.1016\/j.clml.2025.10.009_bib0137","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3332\/ecancer.2018.810","article-title":"Secondary breast cancer after Hodgkin lymphoma: a case report and literature review","volume":"12","author":"Bakkach","year":"2018","journal-title":"Ecancermedicalscience"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:18:53Z","timestamp":1770650333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":137,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042466"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast Cancer Risk After Chest Radiotherapy in Hodgkin Lymphoma Survivors: A Comprehensive Overview","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}